Sektoriaus kontekstas
SELLAS Life Sciences [SLS]
Paskutinį kartą atnaujinta 24 Jun 2026 @ 16:00 (Exchange is closed)
Paskutinė: $9.17
1.10%
4.08
GaG Algo Score™
v1.0
Trumpas
4.08
Vidutinis
5.88 (↑)
Ilgas
5.56 (↑)
PIRKTI
60.00%
grąža 44.76%
PARDUOTI
63.27%
grąža -26.46%
Linija
Pivot duomenys
Pivot statistika
| Rodiklis | Vidurkis | Mediana | Stand. nuokr. |
|---|---|---|---|
| Prieaugis % | 99.14% | 68.84% | 95.62% |
| Nuostolis % | -27.22% | -29.40% | 8.56% |
| Trukmė | 25.2d | 26d | 12.8d |
| Rasta pivot taškų | 11 |
| Prieaugio/nuostolio atkarpos | 10 (5 Prieaugis / 5 Nuostolis) |
| Paskutinis pivot | Top @ $9.17 data 2026-06-24 |
| Pokytis nuo paskutinio pivot | $0.00 (0.00%) |
Kito pivot prognozė Paskutinė: $9.17
| Prognozuojamas kitas tipas | Bottom |
| Prognozuojama kaina (vid.) | $6.67 |
| Prognozuojama kaina (mediana) | $6.47 |
| Prognozuojamas kainos intervalas (~68%) | $5.89 - $7.46 |
| Pokytis iki vidutinio tikslo | $-2.50 (-27.22%) |
| Prognozuojama data (vid.) | 2026-07-19 |
| Prognozuojamas datos intervalas (~68%) | 2026-07-06 - 2026-07-31 |
| Pagrindas | Based on 5 historical losses (Avg: -27.22%, Median: -29.40%, StdDev of Abs: 8.56%) and duration (Avg: 25.2 days, StdDev: 12.8 days) |
| Pastaba | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Modest rise for SELLAS Life Sciences.
SELLAS Life Sciences (SLS) stock price gained some ground on Wednesday after the stock rose $0.1000 (1.10%) from the previous session on below-average volume. The stock showed moderate relative strength, staying flat or rising slightly while the NASDAQ fell -0.43%.(The stock has risen 3 days straight. This extended rally increases the chances of a price pullback soon) With 4.53M shares traded, volume yesterday reached $41.51M. This was 2.72M shares less than the prior day. Compared to the 10-day average of 6.89M shares, volume was less than the average.
SELLAS Life Sciences signals
There is no conclusive signals given from RSI. The price is above both the short- and long-term averages, and the short-term average is above the long-term average, confirming an established up-trend. Strong Bullish Consensus: A powerful wave of positive momentum is evident across all timeframes. Technical indicators are decisively bullish in the short-term (19/30, net +50%), medium-term (19/30, net +50%), and long-term (19/30, net +50%), signaling a robust and sustained uptrend.
SELLAS Life Sciences Support & Resistance Levels
The stock is approaching the closest resistance level at $9.18. approximately $0.01000 (0.11%) away. Pushing up towards resistance. Breaking above this level could signal further upside where next resistance level will be found at $9.31. On a fall back there will be support at $5 The dis das resistance s15 -
SELLAS Life Sciences Evaluation
- Trumpas balas: 4.08
- Vidutinis balas: 5.88
- Ilgas balas: 5.56
Savininkų srautas
GetAGraph InsiderPower
Sandoriai
48
Pirkimo jėga
17.38M
Pardavimo jėga
513.6K
Patikimumas
94/100
Pirk. / pard.
33.84
Ist. korel.
0.06
Naujausias signalas
Buy 2026-06-24
Director 25
Officer 16
Executive 7
2026-06-16
Stergiou Angelos M. Executive
Buy 1 065 000
2026-01-07
Varian John Director
Buy 50 000
2026-01-07
Van Nostrand Robert L Director
Buy 50 000
2026-01-07
Scheinberg David A Director
Buy 50 000
2026-01-07
Cicic Dragan Officer
Buy 300 000
2026-01-07
Burns John Thomas Officer
Buy 300 000
Ryšių žemėlapis
Koreliacijos vaizdas
<span style="background-color: lightcoral">Overvalued: <i class="arrow arrow-down"></i>2.05% <strong>$9.39</strong> paired level.</span>
Įvykių kontekstas
Apimtis ir dividendai
Ilga apimties korel.
0.37
Trumpa apimties korel.
-0.32
Positioning pressure
Short interest pressure
Short interest
57.87%
Of outstanding shares
Short float
58.07%
Of tradable float
Days to cover
4.42
Short interest divided by average volume
Squeeze probability
100.00%
+6.89% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Income profile
Dividend profile
Paskutinis dividendas
$0.420
2010-12-09
Kitas dividendas
$0
N/A
Avg. yearly yield
0.00%
Quarterly
Total paid
$0.570
2 payments
Sustainability
3.00
N/A
Growth potential
3.00
N/A
Direction
3.00
Score based on dividend trend and payout behavior.
Yearly history
| Year | Dividend | Yield |
|---|---|---|
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
Recent payments
| Date | Dividend | Payment |
|---|---|---|
| 2010-12-09 | $0.420 | 2010-12-20 |
| 2010-09-09 | $0.150 | 2010-09-22 |
Earnings quality
Earnings history
Reported quarters
10
EPS beats
5
EPS misses
5
Avg. surprise
-180.59%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q4/2025 | 2025-11-11 | - | - | - | - |
| Q3/2025 | 2025-08-12 | - | $-0.0800 | - | - |
| Q2/2025 | 2025-05-13 | $-0.0700 | $-0.100 | 30.00% | - |
| Q1/2025 | 2025-03-20 | $-0.0800 | $-0.110 | 27.27% | - |
| Q4/2024 | 2024-11-13 | $-0.100 | $-0.130 | 23.08% | - |
| Q3/2024 | 2024-08-13 | $-0.130 | $-0.160 | 18.75% | - |
| Q2/2024 | 2024-05-14 | $-0.210 | $-0.160 | -31.25% | - |
| Q1/2024 | 2024-03-28 | $-0.250 | $0.0867 | -388.45% | - |
Analyst view
Analyst targets
Consensus
$2.80
Median
$2.80
Low
$2.40
High
$3.20
News flow
Latest company news
Market coverage
benzinga.com SELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move? May 20, 2026 globenewswire.com SELLAS Life Sciences to Participate in Upcoming Investor Conferences May 14, 2026 benzinga.com SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses May 13, 2026 globenewswire.com SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update May 12, 2026Company releases
Company context
Company profile
Birža:
NASDAQ
Sektorius:
Healthcare
Pramonė:
Biotechnology
Currency
USD
SELLAS Life Sciences Group Inc a latestage clinical biopharmaceutical company focuses on the development of novel therapeutics for various cancer indications in the United States The companys lead product candidate is galinpepimutS GPS a peptide immunotherapy directed against the Wilms tumor 1 antigen and SLS009 tambiciclib a selective small molecule cyclindependent kinase 9 or CDK9 inhibitor It has a strategic collaboration with Merck Co Inc to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 12 clinical trial enrolling patients in up to five cancer indications including hematologic malignancies and solid tumors GenFleet Therapeutics Shanghai Inc for the development and commercialization of GFH009 and Memorial Sloan Kettering Cancer Center for developing and commercializing MSKs WT1 peptide vaccine technology SELLAS Life Sciences Group Inc is headquartered in New York New York
Navigation